Logos Global Management LP Mirati Therapeutics, Inc. Transaction History

Logos Global Management LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$27.8 - $45.35 $8.34 Million - $13.6 Million	300,000 New	300,000 $13.1 Million
Q2 2022 Aug 15, 2022	SELL	$39.16 - $88.71 $13.7 Million - $31 Million	-350,000 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$75.82 - $150.97 $22.7 Million - $45.3 Million	300,000 Added 600.0%	350,000 $28.8 Million
Q4 2021 Feb 14, 2022	BUY	$132.01 - $190.29 $6.6 Million - $9.51 Million	50,000 New	50,000 $7.34 Million
Q1 2021 May 17, 2021	SELL	$158.92 - $221.61 $7.95 Million - $11.1 Million	-50,000 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$162.05 - $240.27 $8.1 Million - $12 Million	50,000 New	50,000 $11 Million
Q2 2020 Aug 14, 2020	SELL	$72.01 - $120.39 $3.34 Million - $5.59 Million	-46,399 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$69.78 - $116.21 $14.5 Million - $24.1 Million	-207,261 Reduced 81.71%	46,399 $3.57 Million
Q4 2019 Feb 14, 2020	BUY	$70.76 - $128.86 $17.9 Million - $32.7 Million	253,660 New	253,660 $32.7 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Logos Global Management LP, based on Form 13F filings with the SEC.

Stay updated on Logos Global Management LP with notifications on news.